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INTRODUCTION
Every year in Europe and the US, approximately 
550,000 people die of disease related to cardiac 
cell death.1 The fundamental mechanism leading 
to the high morbidity and mortality in patients 
with any form of coronary artery disease is isch-
emia that induces myocardial injury and subse-
quent cardiomyocyte loss. Although the existence 
of cardiac progenitor cells has been reported 
and suggested to indicate a certain regeneration 
capacity,2,3 adult myocardium—unlike skeletal 
muscle—does not show substantial regeneration 
after ischemic or other injury. Consequently, 
cardiomyocyte loss due to disease or injury is 
irreversible and typically results in the replace-
ment of working cardiac tissue with nonfunc-
tional scar tissue. Compensatory hypertrophy of 
the myocardium can, to a limited degree, alleviate 
the loss of contractile function that accompanies 
scar formation. Myocardial hypertrophy, however, 
predisposes the heart to arrhythmia, which 
frequently results in ventricular fibrillation and 
sudden death.4,5
EXISTING APPROACHES FOR CARDIAC 
REGENERATION
Currently, cardiac transplantation is the only 
curative therapeutic option for patients with 
severely diseased hearts. The ability to replace or 
regenerate damaged myocardium with functional, 
coupled cardiomyocytes would have obvious 
therapeutic value. To accomplish these effects, 
several approaches are actively being pursued by 
various research groups. Some work is focused on 
the in vivo manipulation of pre-existing cardiac 
cells, such as through inducing cardiomyocytes to 
reenter the cell cycle in vivo,6 promoting cardiac 
cell migration and survival through the activa-
tion of antiapoptotic proteins (e.g. Akt),7,8 and 
identifying genes that are able to initiate a cardio-
myogenic differentiation, with the hope of being 
able to transdifferentiate cardiac fibroblasts into 
cardiomyocytes.9 
Most groups are focused on the transplanta-
tion of new cells into a diseased heart, with the 
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hope that these cells will successfully contribute 
to host myocardial function. Several cell sources, 
including cells derived from tissues other than 
bone marrow (fetal cardiomyocytes, genetically 
modified skeletal myoblasts, and cardiomyocytes 
derived from embryonic stem cells [ESC]) and 
bone marrow-derived cells, have been success-
fully transplanted into normal hearts, diseased 
hearts, or both.10 
LIMITATIONS OF CELL SOURCES OTHER 
THAN BONE MARROW
Fetal cardiomyocytes and embryonic 
stem cells
The cardiomyogenic potential of ESC from a 
variety of species, including humans, is well estab-
lished. Indeed, fetal cardiomyocytes and ESC-
derived cardiomyocytes stably engraft into and 
electromechanically couple with the myocardium 
of normal and injured adult mouse hearts.11–13 
The therapeutic use of these cells is, however, 
hindered by several ethical and technical caveats. 
The limited availability of fetal cardiomyocytes, 
the difficulty in obtaining pure ESC-derived 
cardiomyocytes without further genetic manipu-
lation,14 the consequent risk of teratoma forma-
tion,15 and the immuno genicity of allogeneic cell 
grafts hamper the use of these cells for clinical 
purposes. Nuclear transfer has been proposed 
as an approach to obtain non immunogenic 
patient-matched ESC. Initial claims of success 
with human ESC had, however, to be withdrawn, 
which was an important setback for this area of 
study.16 Other approaches, such as the induction 
of immunotolerance to a human ESC line by use 
of hematopoietic cells derived from it, are being 
explored. A prerequisite to these approaches is 
the ability to obtain efficient multilineage hemato-
poiesis from human ESC, which has not yet been 
fully accomplished.17 
Skeletal myoblasts and satellite cells 
Skeletal myoblasts are currently being tested as a 
source of cells for cardiac repair. Evidence from 
animal models suggests that implantation of skel-
etal myoblasts leads to an improvement in cardiac 
function. Long-term survival and electrical 
coupling of these cells within the myocardium, 
however, remain controversial. Paracrine mecha-
nisms seem to be responsible, at least in part, for 
the beneficial effects of these myoblasts.18 Clinical 
trials have been started in both Europe and the 
US. So far, they show improvement in most 
participants, although some cases of arrhythmia 
have been detected. This finding is due in part to 
a failed coupling between transplanted and host 
cells. The requirement of defibrillators in some 
patients has been a serious safety concern.19
THE CARDIOMYOGENIC POTENTIAL OF 
BONE MARROW-DERIVED CELL SOURCES
Several investigators have observed putative 
cardiomyogenesis from bone marrow-derived 
cells. For example, studies from the Fukuda labo-
ratory have shown that 5-azacytidine treatment 
of bone marrow stromal cells, also called mesen-
chymal stem cells (MSC), gave rise to sponta-
neously contractile cells with some features 
consistent with cardiomyocytes.20 Subsequent 
analysis indicated that these cells also expressed 
genes determining skeletal myogenic lineage, 
raising the possibility that the cells were partly 
differentiated skeletal myotubes. 
Controversy has risen around the degree 
to which bone marrow cells can contribute to 
the formation of cardiomyocytes. The Anversa 
group has shown that transplantation of Lin–/
c-kithigh hematopoietic progenitors into mouse 
hearts immediately after coronary artery liga-
tion gives rise to around 50% of the cells with 
cardiomyocyte, endothelial, and smooth muscle 
phenotypes, leading to improved cardiac func-
tion.21 Subsequent studies from other groups 
have, however, indicated that, although improved 
function might occur following transplantation 
of Lin–/c-kithigh or nonpurified bone marrow 
cells in cardiac infarcts, significantly less (<1%) 
cardiomyocyte differentiation was obtained.22,23 
Furthermore, the mechanism of lineage switch to 
cardiomyocytes (and vascular cells) is not clear. 
The in vivo contribution to cardiomyogenesis 
would probably be indirect through secretion of 
cytokines, as has been shown for MSC.24
Several reports have suggested that bone 
marrow stem cells possess a much greater degree 
of plasticity than previously believed.25,26 In addi-
tion to the long-recognized hematopoietic, osteo-
genic, chondrogenic, and adipogenic potentials 
of bone marrow cells and stroma, bone marrow 
has been demonstrated to contain cells that form 
skeletal myocytes, hepatocytes, endothelium, 
smooth muscle, and neurons upon transplanta-
tion into adult recipients. Such unexpected plas-
ticity could originate from a common precursor 
or from separate tissue-specific stem-like cells 
residing in the bone marrow. Apparent lineage 
commitment might also be due at least in part to 
fusion with host cells after transplantation.27,28
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BONE MARROW PROGENITORS 
WITH CARDIOMYOGENIC POTENTIAL
Among the different populations of stem cells 
isolated, a population of primitive cells called 
multipotent adult progenitor cells (MAPCs) 
has attracted particular interest. These cells have 
multipotent differentiation and extensive prolif-
eration potential at the single-cell level. Initially 
described by the Verfaillie group, MAPCs have 
been isolated from the bone marrow of a number 
of different types of mammals, including 
humans, nonhuman primate, swine, and 
rodents, and from other mammalian postnatal 
tissues.29–33 After their initial description, other 
groups have also been able to isolate and charac-
terize this rare population of stem cells.34,35
MAPCs are negative for CD44, CD45, major 
histocompatibility complex classes I and II, and 
c-kit and have low concentrations of Flk1. In 
mice, MAPCs also have low levels of Sca1 and 
SSEA-1. This phenotype has allowed these cells 
to be distinguished from other types of stem 
cells, such as hematopoietic stem cells or MSC. 
However, the lack of specific MAPC markers has 
raised questions about whether MAPCs would 
be an in vitro generated cell type without in vivo 
counterpart. We cannot yet completely answer to 
this question, but we have some evidence from 
profiling studies that MAPC are not merely a 
culture artifact. MSC derived under MAPC 
growth conditions could not be converted to an 
MAPC phenotype, and clonal isolation under 
identical culture conditions yielded clones with 
an MAPC signature and others with an MSC 
profile (CM Verfaillie, unpublished data). In 
addition, Anjos-Afonso and Bonnet36 isolated 
SSEA-1 cells from bone marrow that closely 
resemble the MAPC phenotype without the 
need for a lengthy culture procedure. Finally, 
others have presented evidence for the existence 
of octamer-4 (Oct-4)-expressing cells in freshly 
isolated bone marrow.37,38 
Human, swine, and rodent MAPCs can be 
expanded under defined culture conditions 
(2% fetal bovine serum, platelet-derived growth 
factor, epidermal growth factor, and leukemia 
inhibitory factor for rodents) without telomere 
shortening and express the ESC-specific tran-
scription factors Oct-4 and Rex-1 (also known 
as zinc-finger protein 42, Zfp42), with a vari-
able degree of Oct-4 expression among clones. 
When injected in an early blastocyst, one 
murine MAPC contributes to most, if not all, 
somatic cell types, and when transplanted in a 
nonirradiated host, murine MAPCs engraft and 
differentiate to the hematopoietic lineage and 
epithelium of liver, lung, and gut. Engraftment 
is increased when MAPCs are transplanted in a 
minimally irradiated host (CM Verfaillie et al., 
unpublished data).30 
The premise that MAPCs have the intrinsic 
capability to generate cardiomyocytes comes 
from blastocyst injection studies, in which up 
to 45% of the cardiac muscle has been derived 
from a single injected MAPC.30 In addition, 
despite their multiple ESC-like characteristics, 
there is no evidence so far for teratoma forma-
tion after in vivo transplantation of MAPCs. 
We believe, therefore, that MAPCs capable of 
making cardiac and vascular cells could consti-
tute a good source of donor cells for therapeutic 
cellular transplantation in the heart. We have 
examined the potential of MAPCs to contribute 
to cardiac regeneration in models of acute and 
chronic myocardial infarction (see below). A 
model of limb ischemia has also been developed 
for studying the therapeutic potential of MAPCs 
in peripheral vascular disease.
CARDIAC REGENERATION IN CHRONIC 
AND ACUTE CARDIAC ISCHEMIA
We have studied the effect of MAPC transplanta-
tion in a chronic model of myocardial infarction 
in rats. Although transplantation of MAPC was 
associated with reduced remodeling due to the 
increase in left ventricular volumes, stem cells did 
not improve the global pump function. The func-
tional improvement detected could possibly be a 
consequence of favorable changes in the extra-
cellular matrix composition, leading to some 
mechanical stabilization of the ventricular wall. 
Significant angiogenesis or arteriogenesis induc-
tion was not demonstrated in these studies, 
although some endothelial but not cardiomyo-
cyte-differentiated cells were found at early time 
points.39 We have previously shown the ability of 
MAPC to contribute to the cardiac tissue in the 
blastocyst, but the strict environment of chroni-
cally infarcted tissue could limit their survival. In 
addition, signaling clues might not be sufficient 
for directing MAPCs towards cardiac differentia-
tion, which could be responsible for the absence 
of MAPC-derived cardiac cells.
Studies using models that sustain engraft-
ment of MAPCs for a longer period, thus 
allowing assessment of their differentiation 
potential in vivo, are in progress. In our study, 
cell engraftment was observed for up to 2 weeks 
NCPCMSuppl_2006_278.indd   S17 22/12/06   12:12:58 pm
ARTICLE
S18  NATURE CLINICAL PRACTICE  CARDIOVASCULAR MEDICINE    PELACHO ET AL.   FEBRUARY 2007  VOL 4  SUPPLEMENT 1
www.nature.com/clinicalpractice/cardio
after transplantation but 1 month after trans-
plantation, MAPC could not be detected in the 
animals.39 The low engraftment of the injected 
cells could be due to the fact that cells were 
injected 2 weeks after myocardial infarction, at 
the time when healing was still in the granula-
tion phase. Also, the MAPC, which are negative 
for major histocompatibility complex I, were 
transplanted in animals that were not treated 
with an antibody to natural killer, so they might 
have been eliminated by natural killer cells.40 
Given these issues, further experiments are 
required in order to elucidate the potential of 
MAPCs in chronic cardiac ischemia.
We evaluated the long-term effect of in situ 
MAPC transplantation in acutely ischemic 
hearts (CM Verfaillie et al., unpublished results). 
The effect of mouse MAPCs was compared with 
that for bone marrow cells. MAPC reduced 
the infarct size to a greater extent; induced a 
robust neovascularization response, suppos-
edly through cytokine secretion in the ischemic 
heart; and durably improved the left ventricular 
function. Importantly, the establishment of 
a new microvascular network able to nourish 
with oxygen and nutrients the damaged tissue 
or areas at risk could rescue the cardiomyocytes 
from apoptosis and the consequent scar expan-
sion. A clear correlation between the increase in 
vessel number and an improvement of cardiac 
function was found in our study, although a 
direct link between those two events remains to 
be proved.
VASCULAR DIFFERENTIATION IN VITRO 
AND IN VIVO
We have shown that MAPC differentiate 
into cells that express markers of endothelial 
cells and, most importantly, have proved that 
vascular endothelial growth factor induced 
MAPC to function like endothelial cells.31,32 
Physiologically, lipoproteins are modified by 
endothelial cells during transport in the artery 
wall, after which they maintain a permeability 
barrier through intercellular junctions that 
widen when exposed to hemodynamic forces or 
vasoactive agents, such as histamine. Moreover, 
endothelial cells release prothrombotic mole-
cules such as von Willebrand factor, tissue 
factor, and plasminogen activator inhibitor to 
prevent bleeding and regulate leukocyte traf-
ficking by changing expression levels of adhe-
sion mol ecules in response to inflammation. 
Endothelium also reacts to hypoxia by producing 
vascular endothelial growth factor and expressing 
vascular endothelial growth factor receptors to 
increase vascular density. We demonstrated 
that endothelial cells generated from MAPCs 
can perform all these tasks when tested in vitro 
through measurement of von Willebrand factor 
release in response to histamine; acetylated LDL 
uptake; vascular tube formation when plated 
in matrigel substrate; upregulation of vascular 
endothelial growth factor, Flk1, and Tek in 
response to hypoxia; and upregulation of HLA 
in response to inflammatory cytokines, such as 
interleukin 1α.31,32 
The in vivo potential of MAPCs as vascular 
progenitors is of particular interest. Initial 
studies conducted in a lung cancer tumor model 
in nonobese diabetic/severe combined immuno-
deficient (NOD/SCID) mice demonstrated 
that human MAPCs transplanted into the mice 
contributed to up to 35% of the endothelial 
cells in the tumor vessels. This finding suggests 
the in vivo potential for vasculogenesis.31 
Furthermore, we found that MAPC-derived 
endothelial cells generated in vitro respond 
in vivo to angiogenic stimuli by participating 
in wound healing.31 These findings together 
confirm that endothelial cells generated from 
MAPCs have all the functional characteristics 
of mature endothelium. 
Other studies in our laboratory aimed to 
determine the vascular potential of MAPCs in 
comparison with other sources of stem cells with 
recognized potential for vascular differentiation, 
such as AC133+ cells. MAPCs could be specified 
to both arterial and venous endothelia, whereas 
AC133+ cells formed only venous endothelial cells 
under the same culture conditions (F Prosper 
et al., unpublished data). This arterial endothelial 
cell potential, along with the capacity to differ-
entiate into smooth muscle cells, could establish 
MAPCs as an attractive cell source for arterio-
genesis. Indeed, one important feature that has 
not yet been addressed in the studies that claim 
a revascularization effect after stem cell injection 
in ischemic tissue is whether such process is due 
to arterial or venous endothelial differentiation. 
Revascularization should ideally induce arterial 
rather than venous growth, which would supply 
the oxygen required by the ischemic tissue. 
DISCUSSION ON THE CARDIOVASCULAR 
REGENERATIVE POTENTIAL OF MAPC 
We have previously shown that undifferentiated 
murine and human MAPC can differentiate into 
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endothelial cells and can directly contribute to 
blood vessels in tumors.31 In the experiments 
performed in infarcted mice and rats, however, 
MAPCs did not survive in the heart micro-
environment, probably because of an immune 
rejection against the marker protein LacZ or 
green fluorescent protein. We were, therefore, 
unable to assess whether they would have a 
similar capacity in this model. Nevertheless, we 
have preliminary data showing MAPC-derived 
endothelial cells at early time points after cell 
injection in acute infarcted immunosuppressed 
mice or chronic infarcted immunosuppressed 
rats. Moreover, we have evidence that MAPC 
contribute to endothelial cell populations in the 
ischemic limb of the mouse and significantly 
improve hindlimb function (CM Verfaillie et al., 
unpublished data). 
Importantly, we have demonstrated in vitro 
and in vivo the ability of MAPCs to specifically 
differentiate towards arterial or venous endothe-
lium after specific cytokine treatment (F Prosper 
et al., unpublished data). The ability to manipu-
late the cells in that manner could enable regen-
eration of the ischemic tissue and preservation 
of the area at risk by increasing oxygen supply. 
The lack of in vivo cardiac muscle differen-
tiation in ischemic hearts is perhaps surprising 
because we have shown that mouse MAPCs 
injected in the blastocyst can differentiate 
in cardiac muscle cells.30 We have thus far, 
however, been unable to induce a (mature) 
cardiac phenotype in rodent MAPCs in vitro. 
Nevertheless, we have preliminary evidence that 
cardiac specification and commitment might be 
possible in vitro when apparently more-potent 
lines of rodent MAPCs are used.41 Studies are 
in progress in which these MAPC lines in their 
undifferentiated state and following cardiac 
commitment are being grafted in a mouse 
model of acute myocardial infarction.
CONCLUSIONS 
Taking all these data together, we have demon-
strated that MAPCs can functionally improve 
the heart or limb muscle after an ischemic insult 
in rodents. This result was not due only to an 
indirect paracrine effect on neovascularization 
but also through the contribution of MAPC to 
vessels. Very importantly, MAPC can be directed 
towards a specific arterial endothelial cell 
phenotype, a manipulation that could further 
improve and optimize strategies for vascular 
regeneration in ischemic patients and might also 
have implications for the design of endothelial 
cell-coated artificial arterial grafts.
Although additional studies are required to 
prove their in vivo cardiomyogenic potential, we 
now have promising evidence for cardiomyocyte 
specification in vitro after specific sequential 
cytokine treatment of new, more potent MAPC 
clones. On the basis of the encouraging results 
in rodents, it will be interesting to determine 
whether this effect is also apparent in larger 
animal models and, ultimately, in patients with 
cardiac or limb ischemia.
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